Skip to main navigation menu Skip to main content Skip to site footer
×
English | Español
Editorial
Home
Indexing
Review

Cystatin C as an early marker of cardiovascular risk in patients with diabetes

By
Maritza Anabel Tisalema-Panimboza ,
Maritza Anabel Tisalema-Panimboza

Universidad Técnica de Ambato, Facultad Ciencias de la Salud, Carrera de Laboratorio Clínico, Ambato, Ecuador

Search this author on:

PubMed | Google Scholar
Edison Arturo Galárraga-Pérez ,
Edison Arturo Galárraga-Pérez

Universidad Técnica de Ambato, Facultad Ciencias de la Salud, Carrera de Laboratorio Clínico, Ambato, Ecuador

Search this author on:

PubMed | Google Scholar

Abstract

Introduction: Cystatin C, a protein with stable plasma concentration and exclusive renal elimination, has been highlighted as a promising early marker of cardiovascular risk in diabetic patients due to its relationship with renal function and inflammation.
Objective: To identify in the existing literature the association between Cystatin C and cardiovascular risk in patients with diabetes, evaluating its potential as a marker by means of a systematic review.
Methods: We performed exhaustive searches of scientific databases and selected ten studies that met the inclusion criteria. These studies focused on the evaluation of Cystatin C expression profiles and their effectiveness as a marker in the diagnosis and prognosis of cardiovascular disease. The PRISMA method was used.
Results: The studies reveal that cystatin C is closely associated with type 2 diabetes, predicts cardiovascular disease, and provides an accurate assessment of renal function in diabetic patients, highlighting its usefulness as an early marker of complications. Furthermore, elevated cystatin C levels correlate with increased mortality and cardiovascular risk, surpassing in accuracy other traditional markers, positioning it as a key indicator in the comprehensive assessment of risk and prognosis in diabetic patients.
Conclusions: Cystatin C shows promising links with diabetes and cardiovascular risk in diabetic patients, suggesting its usefulness as an early marker. Although it offers the potential for detecting renal and cardiac complications, further research is required before its widespread clinical implementation.

How to Cite

1.
Tisalema-Panimboza MA, Galárraga-Pérez EA. Cystatin C as an early marker of cardiovascular risk in patients with diabetes. Salud, Ciencia y Tecnología [Internet]. 2023 Dec. 12 [cited 2024 Feb. 23];4:684. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/684

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

 

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.